Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Stratmann

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
BMC Research Notes|May 15, 2024
Concepts of lines of therapy in cancer treatment: findings from an expert interview-based studyLisa Falchetto, Bernd Bender, Ian Erhard, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
Plos One|November 25, 2020
Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancerJan A Stratmann, Raphael Lacko, Olivier Ballo, et al.
Chemistry & Biology|February 9, 2000
The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90I Molnár, T Schupp, M Ono, et al.
Journal of Cancer Research and Clinical Oncology|May 17, 2023
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingOliver Kraskowski, Jan A Stratmann, Marcel Wiesweg, et al.
Frontiers in Oncology|October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFriederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Leukemia|August 23, 2022
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemiaSebastian E Koschade, Kevin Klann, Shabnam Shaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2022
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)M Janning, J Süptitz, C Albers-Leischner, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 MutationsFelix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
BMC Research Notes|May 15, 2024
Concepts of lines of therapy in cancer treatment: findings from an expert interview-based studyLisa Falchetto, Bernd Bender, Ian Erhard, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
Plos One|November 25, 2020
Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancerJan A Stratmann, Raphael Lacko, Olivier Ballo, et al.
Chemistry & Biology|February 9, 2000
The biosynthetic gene cluster for the microtubule-stabilizing agents epothilones A and B from Sorangium cellulosum So ce90I Molnár, T Schupp, M Ono, et al.
Journal of Cancer Research and Clinical Oncology|May 17, 2023
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world settingOliver Kraskowski, Jan A Stratmann, Marcel Wiesweg, et al.
Frontiers in Oncology|October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFriederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Leukemia|August 23, 2022
Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemiaSebastian E Koschade, Kevin Klann, Shabnam Shaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2022
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)M Janning, J Süptitz, C Albers-Leischner, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2021
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 MutationsFelix C Saalfeld, Carina Wenzel, Petros Christopoulos, et al.
Pageof 6